Methods of modulating T cell-mediated immune responses with anti-P-selectin glycoprotein ligand 1 antibodies
AssigneeAbGenomics Cooperatief U.A.
InventorsRong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
Life of this patent
Estimating the term…
Abstract
Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
Claims23
A method of delaying or reducing a T cell-mediated immune response in an individual, the method comprising:
- selecting an anti-PSGL-1 antibody based on its ability both to bind specifically to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of an activated T cell and to induce apoptosis of the activated T cell;
- and
- administering to an individual diagnosed as having a condition characterized by an excessive or unwanted T cell-mediated immune response a composition comprising an effective amount of the selected apoptosis-inducing anti-PSGL-1 antibody or an antigen-binding fragment thereof to delay or reduce the T cell-mediated immune response in the individual.
A method of inducing death of a T cell or natural killer (NK) cell, the method comprising:
- selecting an anti-PSGL-1 antibody based on its ability both to bind specifically to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of an activated T cell or NK cell and to induce apoptosis of the activated T cell or NK cell;
- providing a T cell or NK cell expressing PSGL-1 on its cell surface;
- and
- contacting the T cell or NK cell with an effective amount of the selected apoptosis-inducing antibody or an antigen-binding fragment thereof to induce apoptosis of the T cell or NK cell.
A method of delaying or reducing a T cell-mediated immune response in an individual, the method comprising:
- selecting an anti-PSGL-1 antibody based on its ability both to bind specifically to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of an activated T cell and to induce apoptosis of the activated T cell;
- and
- administering to an individual diagnosed as having or as being at risk of acquiring a condition characterized by an excessive or unwanted T cell-mediated immune response a composition comprising an effective amount of the selected apoptosis-inducing anti-PSGL-1 antibody or an antigen-binding fragment thereof to delay or reduce the T cell-mediated immune response in the individual, and wherein the condition characterized by an excessive or unwanted T cell-mediated immune response is an autoimmune disease, rejection of allogeneic or xenogeneic transplant, an allergic disease or a T cell cancer.
Dependencies are inferred from the claim text.